Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-guided Selective Supraclavicular Nerve Block for Postoperative Pain Control in Pediatric Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients receiving Hickman catheter, chemoport, or Perm cath implantation (3 years ≤, \<18 years)~* One or more of the parents (or guardians), after hearing and understanding a sufficient explanation about this clinical trial, decides to participate voluntarily and agrees in writing to abide by the precautions~* In the case of a study subject aged seven years or older, a person who voluntarily decides to participate in this clinical trial and agrees in writing to abide by the precautions after hearing and understanding a sufficient explanation about this clinical trial~Exclusion Criteria:~* Patients who undergo surgery other than the surgery.~* Patients with diseases whose sensitivity to pain is different from that of the general public~* Unstable vital signs (heart rate, blood pressure)~* General contraindications of Ropivacaine~* Patients with a history of allergy to opioids~* Severe renal dysfunction (Creatinine\> 3.0 mg/dl)~* Severe liver dysfunction (aspartate transaminase \> 120 unit/L, alanine aminotransferase \> 120 unit/L)~* Peripheral nervous system abnormalities~* At risk of malignant hyperthermia~* Other cases that the researcher judges to be inappropriate

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Selective supraclavicular nerve block (Type: EXPERIMENTAL): After induction of anesthesia, the anesthesiologist sterilizes the skin of the area to be punctured. In the test group, an Ultrasound-guided selective supraclavicular nerve block is performed using 0.5% Ropivacaine 0.1mL/kg (Maximum dose: 5mL).
- Control (Type: ACTIVE_COMPARATOR): The nerve block is not performed in the control group.

Based on this trial design, predict the completion outcome and termination type (if applicable).